Last reviewed · How we verify
HSS 3%
HSS 3% is a hypertonic saline solution that draws fluid from tissues into the vascular space through osmotic gradient, reducing intracranial pressure and cerebral edema.
HSS 3% is a hypertonic saline solution that draws fluid from tissues into the vascular space through osmotic gradient, reducing intracranial pressure and cerebral edema. Used for Acute intracranial hypertension and cerebral edema, Traumatic brain injury, Stroke with cerebral swelling.
At a glance
| Generic name | HSS 3% |
|---|---|
| Sponsor | Ministry of Health, Spain |
| Drug class | Osmotic agent / Hypertonic saline |
| Modality | Small molecule |
| Therapeutic area | Neurology / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Hypertonic saline (3% sodium chloride) creates an osmotic gradient that pulls interstitial and intracellular fluid into the intravascular compartment, thereby reducing brain swelling and intracranial pressure. This mechanism is particularly useful in acute neurological emergencies where rapid reduction of cerebral edema is critical. The solution also has anti-inflammatory properties that may contribute to neuroprotection.
Approved indications
- Acute intracranial hypertension and cerebral edema
- Traumatic brain injury
- Stroke with cerebral swelling
Common side effects
- Hyperchloremic acidosis
- Hypernatremia
- Phlebitis at infusion site
- Renal dysfunction
Key clinical trials
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN) (NA)
- IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE) (NA)
- A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines (PHASE3)
- A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (PHASE3)
- Cell Content of Sputum Induced by Hypertonic Saline in Adolescents With Cystic Fibrosis (NA)
- Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSS 3% CI brief — competitive landscape report
- HSS 3% updates RSS · CI watch RSS
- Ministry of Health, Spain portfolio CI